CAPR, | Page 1 | RegMed Investors

utility

header_second

RegMed Investors (RMi) went exclusive on July 27th!

Your complimentary subscription to RegMed Investors’ (RMi) reporting on the stem, cell and gene therapy and RegMed sector has expired.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

It’s up to you to choose the level of content access to provide a premium experience and value - don’t wait to exhale!

I also bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of trading, investment or I-Banking.

So, after these years of following our facts … first and fast; be part of our “inner circle” as a subscriber!

Stay with me and join our coalition and have a seat at the appreciation table!

Login Sign up now Not now

content_top

34 companies, 1 interpreter! Insight, foresight
and recommendation

0

content_middle

content_right

January 21, 2026 - 3:03pm | Out and About, Research Notes, Out and About
RMi Research Note: Capricor Therapeutics (CAPR) Provides Regulatory Update on Deramiocel BLA

CAPR
December 18, 2025 - 6:18pm | Out and About, Research Notes, Out and About
RMi Research Note: Capricor Therapeutics (CAPR) I am NOT the ONLY dissenter

CAPR
December 5, 2025 - 10:15am | Out and About, Research Notes, Out and About, Financings
RegMedInvestors (RMi) Financing: Capricor Therapeutics (CAPR) prices offering of 6 M shares at $25.00 per share with ... skepticism!

CAPR
March 10, 2018 - 9:22am | Earnings, Earnings Q4
Regenerative Medicine Earnings Scorecard - Q4 and FY17 - to date
March 4, 2018 - 11:11am | Analysis, Out and About
RegMed Investors’ (RMi) wrapping-up January and February while determining March’s strength …
January 16, 2018 - 7:49am | Out and About
Capricor (CAPR) Licenses additional patent applications from Cedars-Sinai Medical Center (CSMC) for cellular and exosome-based technologies
November 3, 2017 - 1:08pm | Earnings, Earnings Q3
Regenerative Medicine Earnings Scorecard - Q3/2017 - to date
May 12, 2017 - 5:42pm | Out and About, Research Notes
Capricor (CAPR) bites the bullet that they fired at itself
May 8, 2017 - 8:55am | Out and About, Financings
Capricor Therapeutics (CAPR) 1.96 M share offering priced at $3.10
May 5, 2017 - 8:59am | Earnings, Earnings Q1
Regenerative Medicine Earnings Scorecard - Q1/2017 - to date
April 1, 2017 - 8:23am | Research Notes, Financings
Capricor Therapeutics (CAPR) at-the-market offering of $5 M
March 27, 2017 - 12:52pm | Out and About, Research Notes
RegMed Investors’ (RMi) mid-day analysis, retracing
March 10, 2017 - 12:00am | Earnings, Earnings Q4
Regenerative Medicine Earnings Scorecard - Q4/2016 - to date
February 9, 2017 - 1:13pm | Research Notes
RegMed Investors’ (RMi) mid-day analysis, momentum has a short fuse
November 2, 2016 - 8:46pm | Earnings, Earnings Q3
Regenerative Medicine Earnings Scorecard - Q3/2016 - to date
October 20, 2016 - 9:07am | Research Notes
Capricor Therapeutics (CAPR) NIH grant of $4.2 M to Evaluate Exosomes for Hypoplastic Left Heart Syndrome
September 15, 2016 - 5:38pm | Research Notes, Financings
Capricor Therapeutics (CAPR) proposes public offering of 3 M shares at $3.20
August 4, 2016 - 10:50pm | Earnings, Earnings Q2
Regenerative Medicine Earnings Scorecard - Q2/2016 - to date
March 15, 2016 - 9:18am | Henry'omics, Financings
Capricor Therapeutics (CAPR) $4 M offering of 1.692 M shares at $2.40
February 23, 2016 - 12:43pm | Henry'omics, BOD & C-Suite Updates
Capricor (CAPR) prepares for a financing with addition of new CFO …

Pages

footer

© 2015 RegMed Investors (regmedinvestors.com), all rights are reserved.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry MCusker . Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of RegMed Investors (RM-i); who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other RM-i media services or reposting please email hwm@regmedinvestors.com.